Enhanced sequence coverage of proteins in human cerebrospinal fluid using multiple enzymatic digestion and linear ion trap LC-MS/MS

Briefings in Functional Genomics and Proteomics

Volumn 5, Issue 2, 2006, Pages 144-153

  Biringer, Roger G ^a   Amato, Heidi ^b   Harrington, Michael G ^b   Fonteh, Alfred N ^b   Riggins, James N ^b   Hühmer, Andreas F R ^a  

^a Thermo Fisher Scientific   (United States)

^b NONE

Author keywords

Glutamic acid endopeptidase; Trypsin

Indexed keywords

ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ANGIOTENSINOGEN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN D; APOLIPOPROTEIN E; ARGININE CARBOXYPEPTIDASE; CERULOPLASMIN; CHROMOGRANIN B; CHYMOTRYPSIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYSTATIN C; GELSOLIN; GLUTAMATE DECARBOXYLASE; HAPTOGLOBIN; HEMOPEXIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; KININOGEN; OROSOMUCOID; OSTEOPONTIN; PREALBUMIN; PROTEINASE INHIBITOR; TRYPSIN; VITAMIN D BINDING PROTEIN; ARGININE ENDOPEPTIDASE; PEPTIDE HYDROLASE; PROTEOME; SERINE PROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; BRAIN DISEASE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENZYME DEGRADATION; HUMAN; HUMAN TISSUE; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; NEUROLOGIC EXAMINATION; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PROCESSING; REVERSED PHASE LIQUID CHROMATOGRAPHY; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY; CEREBROSPINAL FLUID; CHEMISTRY; COMPARATIVE STUDY; GENETICS; MASS SPECTROMETRY; METHODOLOGY; MOLECULAR GENETICS; REVIEW;

AMINO ACID SEQUENCE; CEREBROSPINAL FLUID; CHROMATOGRAPHY, LIQUID; CHYMOTRYPSIN; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDE HYDROLASES; PROTEOME; SERINE ENDOPEPTIDASES; TRYPSIN;

EID: 33748573295     PISSN: 14739550     EISSN: 14774062     Source Type: Journal    
DOI: 10.1093/bfgp/ell026     Document Type: Article

References (33)

1. Fishman RA. Cerebrospinal fluid in diseases of the nervous system. Philadelphia, W.B. Saunders Company, 1980.
2. Tourtellotte WW, Staugaitis SM, Walsh MJ, et al. The basis of intra-blood-brain-barrier IgG synthesis. Ann Neurol 1985; 17:21-7.
3. Wiltfang J, Lewczuk P, Riederer P, et al. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005;6:69-84.
4. Harrington MG, Merril CR. Two-dimensional electrophoresis and "ultrasensitive" silver staining of cerebrospinal fluid proteins in neurological diseases. Clin Chem 1984;30: 1933-7.
5. Harrington MG, Merril CR, Torrey EF. Differences in cerebrospinal fluid proteins between patients with schizophrenia and normal persons. Clin Chem 1985;31:722-6.
6. Harrington MG, Merril CR, Asher DM, Gajdusek DC. Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N Engl J Med 1986;315: 279-83.
7. Hsich G, Kenney K, Gibbs CJ, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335: 924-30.
8. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1143-53.
9. Huhmer AF, Biringer RG, Amato H, et al. Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges. Dis Markers 2006;22:211-34.
10. Biringer RG, Hao Z, Harrington M, Hühmer AFR. Combined top-down, middle-down and bottom-up analysis of apo A1 and PTGDS isolated from human CSF using ETD-linear ion trap and FT-mass spectrometry. In: American Society for Mass Spectrometry Annual Meeting. Edition San Antonio, TX, 2005.
11. Yun M, Wu W, Hood L, Harrington M. Human cerebrospinal fluid protein database: Edition 1992. Electrophoresis 1992;13:1002-13.
12. Davidsson P, Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 2005;21:81-92.
13. Biringer RG, Harrington MG, Stochaj W, Bondarenko P, Huhmer A, Amato H, Chu G, Swedberg S. Identification of proteins from human cerebrospinal fluid by two-dimensional electrophoresis and ion-trap mass spectrometry: improved sample preparation and presentation methods. Abstract P112-S, At: http://abrf.org/Other/ABRFMeetings/ABRF2002/2002Abstracts.html. In Edition 2002.
14. Dumont D, Noben JP, Raus J, et al. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004;4:2117-24.
15. Hakansson K, Emmett MR, Marshall AG, et al. Structural analysis of 2D-gel-separated glycoproteins from human cerebrospinal fluid by tandem high-resolution mass spectrometry. J Proteome Res 2003;2:581-8.
16. Hammack BN, Fung KY, Hunsucker SW, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004;10:245-60.
17. Akerman S, Goadsby PJ. Topiramate inhibits trigemino-vascular activation: An intravital microscopy study. Br J Pharmacol 2005;146:7-14.
18. Ramstrom J, Hagman C, Mitchell JK, et al. Depletion of high-abundant proteins in body fluids prior to liquid chromatography fourier transform ion cyclotron resonance mass spectrometry. J Proteome Res 2005;4:410-6.
19. Raymackers J, Daniels A, De Brabandere V, et al. Identification of two-dimensionally separated human cerebrospinal fluid proteins by N-terminal sequencing, matrix-assisted laser desorption/ionization - mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometry, and tandem mass spectrometry. Electrophoresis 2000;21:2266-83.
20. Wenner BR, Lovell MA, Lynn BC. Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res 2004;3:97-103.
21. Yuan X, Desiderio DM. Proteomics analysis of phosphotyrosyl-proteins in human lumbar cerebrospinal fluid. J Proteome Res 2003;2:476-87.
22. Yuan X, Desiderio DM. Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics 2005;5: 541-50.
23. Zhang J, Goodlett DR, Peskind ER, et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 2005;26:207-27.
24. Zheng PP, Luider TM, Pieters R, et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003;62:855-62.
25. Harrington MG, Biringer RF, Huhmer AF, Fonteh AN. Cerebrospinal fluid protein composition. J Neurochem 2005; 94:17.
26. Missler M, Sudhof TC. Neurexins: Three genes and 1001 products. Trends Genet 1998;14:20-6.
27. Harrington MG, Fonteh AN, Biringer RG, et al. Prostaglandin D synthase isoforms from cerebrospinal fluid vary with brain pathology. Dis Markers 2006;22:73-81.
28. Aebersold RH, Leavitt J, Saavedra RA, et al. Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose. Proc Natl Acad Sci USA 1987; 84:6970-4.
29. Choudhary G, Wu SL, Shieh P, Hancock WS. Multiple enzymatic digestion for enhanced sequence coverage of proteins in complex proteomic mixtures using capillary LC with ion trap MS/MS. J Proteome Res 2003;2:59-67.
30. MacCoss MJ, McDonald WH, Saraf A, et al. Shotgun identification of protein modifications from protein complexes and lens tissue. Proc Natl Acad Sci USA 2002;99:7900-5.
31. Yi EC, Marelli M, Lee H, Purvine SO, Aebersold R, Aiychison JD, Goodlett DR. Approaching complete peroxisome characterization by gas-phase fractionation. Electrophoresis 2002;18:3205-16.
32. Eng JK. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 1994;5:976-89.
33. Washburn MP, Wolters D, Yates JR, 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001;19: 242-7.